EU_flag_and_co-funded_by_health_programme.jpg

Clinical trials

Competitive Trials Search Excel Results

Trial Title Disease Type(s) Trial Phase(s) Sponsor(s) Primary Drugs Other Drugs Download
Studio randomizzato in doppio cieco controllato con placebo sulla sicurezza e l’efficacia di amatuximab in combinazione con pemetrexed e cisplatino in soggetti con mesotelioma pleurico maligno non resecabile” Codice: MORAb-009 Mesothelioma II Morphotek Amatuximab Pemetrexed
Cisplatino
 
Studio in doppio cieco, randomizzato, di fase II, multicentrico, di Nintedanib in combinazione con Pemetressato/Cisplatino seguito da monoterapia con Nintedanib verso Placebo in combinazione con Pemetressato/Cisplatino seguito da monoterapia con Placebo per il trattamento dei pazienti con mesotelioma pleurico maligno non resecabile Mesothelioma II Boehringer Ingelheim Nintedanib Pemetrexed
Cisplatino
 
A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line platinum/pemetrexed-based chemotherapy” Mesothelioma II Bayer S.p.A. anetumab ravtansine vinorelbine  
An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given Twice Daily in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies (N/A)
Bladder
Colorectal
Leukemia, Chronic Lymphocytic
Liver
Lung, Small Cell
Lymphoma, Hodgkin`s
Lymphoma, Non-Hodgkin`s
Mesothelioma
Ovarian
I Bayer AG/Bayer roniciclib (oral solution)
roniciclib (tablet)
aprepitant  
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications (N/A)
Bladder
Breast
Colorectal
Esophageal
Gastric
Head/Neck
Lung, Non-Small Cell
Melanoma
Mesothelioma
Ovarian
Pancreas
Prostate
Renal
I Merck KGaA/EMD Serono {EMD Pharmaceuticals}
National Institutes of Health/National Cancer Institute
avelumab    
A phase I / II trial to investigate GL-ONC1, a genetically modified Vaccinia virus to patients with malignant pleural effusion in primary lung carcinoma, metastases and mesothelioma applied intrapleurally. Lung, Non-Small Cell
Mesothelioma
Metastatic Cancer
I/II Genelux Corporation GL-ONC1 (intrapleural)
GL-ONC1 (IV)
   
NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM) Mesothelioma II Molmed NGR-TNF    
Pleurectomy and decortication and hypterthermic intrathoracic chemotherapy compared to pleurectomy and decortication in patients with malignant pleural mesothelioma Mesothelioma II (Other Hospital/Academic/Medical Center) cisplatin
doxorubicin
hyperthermia
surgical intervention
   
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma. Mesothelioma II Eisai/Morphotek amatuximab cisplatin
pemetrexed disodium
 
Phase II Trial of Pemetrexed and Cisplatin or Carboplatin in Combination With NovoTTF Therapy as First-line Treatment in Malignant Pleural Mesothelioma Mesothelioma II (Other Industry Sponsor) carboplatin
cisplatin
medical device therapy
pemetrexed disodium
   
A Phase IIb, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma Mesothelioma II/III AstraZeneca/MedImmune tremelimumab    
Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma Mesothelioma II/III Boehringer Ingelheim nintedanib cisplatin
pemetrexed disodium
 
Trimodality Therapy for Malignant Pleural Mesothelioma: Radical Pleurectomy, Followed by Adjuvant Chemotherapy With Cisplatin/Pemetrexed and Radiotherapy Mesothelioma IV (Other Hospital/Academic/Medical Center) cisplatin
pemetrexed disodium
radiation therapy
surgical intervention
   
A Phase II randomized, double-blind, placebo-controlled, multicenter study of VS-6063 in subjects with malignant pleural mesothelioma Malignant Pleural Mesothelioma II Advanced
Aggressive
Classical
Extensive
Indolent
Nodular lymphocyte-predominant
Second line or greater/Refractory/Relapsed
Stage III
Stage IV
Verastem, Inc.    
Phase II trial of anetumab ravtansine (BAY 94-9343) in patients with advanced or metastatic malignant pleural mesothelioma (MPM) overexpressing mesothelin after first line treatment with platinum in combination with pemetrexed Malignant Pleural Mesothelioma II   Bayer  Vinorelbine  
Open Label Phase II Clinical Trial of Pemetrexed and cisplatin or carboplatin in combination with TTFields as First-line Treatment in Malignant Pleural Mesothelioma (STELLAR) Malignant Pleural Mesothelioma II   NovoCure Ltd    
A randomised Phase II open-label study with a Phase Ib safety lead-in cohort of GM-CSF coding oncolytic adenovirus ONCOS-102 and cyclophosphamide in combination with pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma Malignant Pleural Mesothelioma Ib/II   Targovax Oy

Cisplatin and pemetrexed